You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 34800 results
  1. High-Resolution, Spinal Cord Stimulation for Non-Opioid Treatment of Neuropathic Pain

    SBC: MICRO-LEADS INC            Topic: 000

    In this SBIR FastTrack proposal, Micro-Leads will develop HD64—a high-resolution, 64- channel spinal cord stimulation therapy to provide more pain relief with greater specificity for those suffering from chronic neuropathic pain and opioid dependence. Over 25 million in the U.S. suffer from debilitating pain in the trunk and extremities and 55% depend on opioids to ease their suffering. Opioid a ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    SBC: ADVANTAGENE, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therapy for prostate cancer. The desired outcomes are improved local control rate, decreased recurrence and improved disease-free survival. This grant ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. X-Ray Detectors for Synchrotron-Based Structural Biology

    SBC: AREA DETECTOR SYSTEMS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Development is proposed of an x-ray Pixel Array Detector (PAD) consisting approximately of 2,000 x 2,000 pixels to enhance macromolecular crystallographic data collection at synchrotron sources. A PAD consists of an x-ray sensing integrated circuit layer bonded to a pixel electronics layer such that each pixel has its own processing electronics. PADs promise t ...

    SBIR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  4. A Tunable, Tabletop, Synchrotron Light Source

    SBC: LYNCEAN TECHNOLOGIES, INC.            Topic: N/A

    N/A

    SBIR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  5. Organized Lipid Matrix: Fatty Acids and Choline in CF

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased levels of linoleic acid and an increased triene/tetraene ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Risperidone Subcutaneous Implant

    SBC: DELPOR INC            Topic: 101

    The objective of the proposed study is to develop a subcutaneous implant of risperidone that provides consistent therapeutic blood levels of the drug for 6 months after a single administration. The device is implanted during a simple, 10-minute, in-office procedure with local anesthetic. The benefits of the product include improved medication adherence, fewer relapses, ability to withdraw the medi ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Small blood pumps for small patients

    SBC: Vadovations, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Heart failure and congenital heart defects threaten the lives of several thousand children each year The only FDA approved long term pediatric heart support device is the Berlin Heart Excor which is based on year old technology and is fraught with complications including blood clots forming in the device requiring frequent device replacement The recipien ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Fludase for Prevention of Influenza

    SBC: Nexbio, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza is characterized by recurrent annual epidemics and periodic major worldwide pandemics. Because of the high disease-related morbidity and mortality, direct and indirect socio-economic impacts of influenza are enormous. In the last 100 years, there have been 3 major influenza pandemics. It has been about thirty years since the last pandemic. A new pand ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Antiviral Drugs for Lassa Fever Virus

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder

    SBC: LOHOCLA RESEARCH CORPORATION            Topic: 150

    Abstract for Supplement ApplicationThe ultimate goal for our original project was to complete the proof-of-concept work, and the multitude of pharmacodynamic, pharmacokinetic, toxicokinetic, safety, and toxicology studies required by the FDA to apply for an IND. We are fully satisfied that we have generated a new chemical entity that acts at a novel binding site on the GABA-A receptor and acts in ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government